Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_assertion type Assertion NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_head.
- NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_assertion wasGeneratedBy ECO_0000203 NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_provenance.
- NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_assertion wasDerivedFrom befree-2016 NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_provenance.
- NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_assertion SIO_000772 17992582 NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_provenance.
- NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_assertion evidence source_evidence_literature NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_provenance.
- NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_assertion description "[Ultimately, molecularly based designer pharmaceuticals may emerge from this research, such as the case of trastuzumab (Herceptin) in HER-2/neu positive breast cancer, and imatinib (Gleevec) in chronic myelocytic leukemia and gastrointestinal stromal tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP639629.RA9lFrsTgeOJJ2g2U40v1Z3DZCkwHRY7DrRxF_Mto49mA130_provenance.